Maximizers and accumulators have rewritten the rules of providing patient assistance.
The next chapter belongs to program sponsors who are willing to evolve.

The patient affordability problem did not emerge overnight and it will not be solved by yesterday’s solutions. The proliferation of copay maximizers and accumulator programs has redirected an estimated $6.5 billion of manufacturer-sponsored patient copay assistance funds to the benefit of payers instead, with maximizer adoption surging to impact 47% of commercially insured lives in 2024.1 By late 2025, roughly four in ten commercially insured lives were enrolled in plans using one of these programs.2 For pharmaceutical brands, this isn’t a temporary disruption—it’s a structural shift that demands a fundamentally different kind of response.

Yet across the industry, many copay programs still operate on outdated assumptions. These programs rely on broad, undifferentiated tactics that treat every patient situation identically, leaving significant savings on the table and creating gaps where patients fall through. Research consistently demonstrates that higher out-of-pocket costs drive therapy abandonment, evidenced by prescription abandonment rates climbing dramatically once costs exceed even modest thresholds.3 The brands gaining ground today are the ones that have moved past the one-size-fits-all approach in favor of something more disciplined: precision-driven, intelligent program design, continuous adaptation, and a genuine commitment to partnership rather than a transactional vendor relationship.4 That shift in mindset is where real progress begins.

Precision Over Volume: What Intelligent Program Design Actually Delivers
The conventional approach to maximizer mitigation has a fundamental flaw: it either waits too long to intercede or casts too wide a net. Effective, accurate maximizer solutions require a different architecture: one that’s built intelligently around claims-based data and operates in the sweet spot other approaches miss. Legacy solutions are slow to identify maximizerimpacted claims, often not responding until the second or third fill. This can result in diverted program dollars and negative gross-to-net impact.

Other solutions rely on patient-reported data gathered at enrollment, such as payer, plan type, and deductible. Aside from the potential for data degradation or manufacturers who decline to collect that level of detail, the mechanism for identifying potential maximizer impacts is just a guess. Without the required precision, misidentified patients may experience added friction and increased abandonment rates.

Claims-based solutions operate differently by using advanced logic. They analyze actual pharmacy claims in real time, addressing maximizer behavior at the first fill with identification accuracy in the range of 97–98 percent.5 These intelligently designed solutions adapt dynamically to any changes in a patient’s program status, including maximizer impact or changes to insurance. The solution adjusts program rules instantly when an impacted patient is identified. All this happens seamlessly, behind the scenes, without causing friction or requiring involvement from the patient or program sponsor.

Manufacturers should expect new operational standards of their solution partners including real-time identification at first fill, instant dynamic program adjustments, evidence-based, targeted expansion processes, and daily impact reporting. Solution providers leveraging all these tools have protected hundreds of millions of dollars in copay program funds each year.5

The Hidden Cost of Friction: Why Transitions Determine Adherence
Traditional copay program transition methodologies place too much of the burden on the patient leading to potential abandonment of therapy. This is a complete misunderstanding of the copay environment. Bestin-class program transitions should be invisible to patients, with the work happening behind the scenes in communication with the appropriate stakeholder—the pharmacy. Manufacturers should assess a potential partner’s transition methodology with the same rigor applied to ongoing program capabilities, because a seamless transition is a measurable driver of retention, adherence, and long-term therapy value.

A Disciplined Strategy: Targeted Expansion and Operational Transparency
Because maximizer programs differ in how they operate, most payers do not use a wide, one-size-fits-all deployment across therapeutic areas.6 Therefore, a mitigation solution that works against one maximizer configuration may not translate directly to another. This is where disciplined expansion matters. Effective service providers don’t chase coverage by bolting on untested, catch-all capabilities; they grow their solution’s reach through methodical investigation and evidencebased validation, ensuring that each expansion maintains the same standard of first-fill accuracy and minimal patient disruption.

When copay providers deploy broad, untested tactics to accelerate maximizer coverage, that discipline is absent and the result is predictable: higher error rates, confused patients, and avoidable therapy abandonment. Manufacturers should view their provider’s expansion methodology as a direct indicator of the quality they can expect at scale.

An underappreciated competitive differentiator in patient affordability is transparency; not as a marketing claim but as an operational commitment. Many legacy providers offer summary-level reporting but manufacturers should expect more:

    • Granular daily reporting on solution performance across individual maximizer programs
    • Ongoing updates on expansion progress and targeting refinements
    • Clear escalation protocols for any misidentified patients
    • Comprehensive adherence analytics that connect program activity to patient outcomes

This level of visibility isn’t a luxury—it’s the baseline for any provider claiming to offer a mature maximizer solution. Pricing transparency and operational honesty must extend across the entire patient affordability ecosystem.

The Standard Has Changed, Time to Choose Your Advantages
As pressures on the patient affordability landscape continue to mount, the gap between the manufacturers who have a true solution partner committed to their success and those without will widen—not because the challenges can’t be overcome, but because the margin for error in program design, operation, and performance is shrinking. The manufacturers best positioned for what comes next are partnered with innovative, dynamic solution providers who offer intelligent program architecture: demanding claims-based identification accuracy, seamless transition capability, and daily impact reporting as basic requirements. These providers are partners who treat program design as an ongoing, evolving discipline, rather than a one-time implementation, and demonstrate that commitment publicly over time.7 The measure of an effective copay program is not how many claims were processed; it is how many patients stayed on their prescribed therapy because access was never a question.

 

REFERENCES:
  1. Fein AJ. Why plan sponsors and PBMs are still falling hard for copay maximizers. Drug Channels. February 12, 2025. https://www.drugchannels.net/2025/02/why-plan-sponsors-and-pbms-are-still.html
  2. Fein AJ. Copay accumulators and maximizers in 2025: popular, profitable, and problematic. Drug Channels. February 10, 2026. https://www.drugchannels.net/2026/02/copay-accumulators-and-maximizersin.html
  3. Rose JZ. Medication adherence is not a zero-sum game. Am J Manag Care (AJMC). December 25, 2025. https://www.ajmc.com/view/contributor-medication-adherence-is-not-a-zero-sum-game
  4. Melchione L. Reshaping patient affordability: the power of expertise and agility. Drug Channels / PM360. March 2026. https://www.drugchannels.net/2026/03/reshaping-patient-affordability-power.html
  5. Paysign, Inc. Paysign, Inc. announces 2025 performance analysis of patient affordability solutions. Paysign.com. January 7, 2026. https://paysign.com/paysign-inc-announces-2025-performance-analysis-ofpatient-affordability-solutions/
  6. MMIT. Inside the payer playbook: copay accumulators and maximizers, Part 1. MMIT Thought Leadership. January 22, 2026. https://www.mmitnetwork.com/thought-leadership/inside-payerplaybook-copay-accumulators-maximizers-part-1/
  7. Melchione L. Copay comes full circle: an industry ready for disruption. Drug Channels / Paysign.com. March 8, 2024. https://paysign.com/copay-comes-full-circle-an-industry-ready-for-disruption/